Investment Advice

The AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI can only make invest

By Terry Tanaka 05 Jul, 2026
The AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI AI can only make invest
While demand is unlikely to be negatively impacted, new AI tools will reduce costs and enhance healthcare research

Should you pursue a career in healthcare?

Artificial intelligence (AI), which is transforming data-intensive industries, is especially well-positioned to help the healthcare sector. If there's one thing AI can do better than anything else, it is to sort, analyse and draw patterns from data. The healthcare industry has the most data of any industry.

We can now interpret CT scans in milliseconds, search through drug trial data in minutes instead of months, and find new treatments by analyzing hundreds of previous studies thanks to AI tools and increased computing power. Five years ago, researchers could only have imagined the results that are being unlocked by this.

Additionally, AI is unlikely to be demand for demand for AI. Humans won't stop getting ill as tech gets better. They may even require more healthcare as AI unveils more solutions to previously incurable diseases and extends lifespans.

However, the market does not seem to care about the market. Investors are going all-in on the market's leading AI companies, but they are ignoring this thematic play.

AI profit margin profit margin profit margin profit margin profit margin profit margin profit margin profit margin profit margin.

The valuation of the global healthcare sector is trading broadly in line with its own long-term history, according to broker Panmure Liberum. But when normalized profit margins are taken into account, it's trading at levels not seen since 2009-2012. That is because margins have fallen from 10 percent to 6 percent-7 percent over the past five years as costs have risen a trend that AI should help to reverse.

Trading is a trading at a trading at a discount.

On a normalized earnings basis, the healthcare industry as a whole is trading at a discount of about 50% to the MSCI All Countries World Index (ACWI). However, this is not the case in the pharmaceutical subsector. It appears to be on a price; however, but it is adjusted; however, the price; however, the price; however, as follows: 18).

Nevertheless, both industries are worth a higher price. The MSCI ACWI Healthcare and MSCI ACWI Pharmaceuticals sectors have reported revenue growth of 7.6 percent and 5.9 percent annually over the last ten years, respectively, while the overall MSCI ACWI has reported revenue growth of 2.5 percent. The Earnings of the Earnings of the Earnings of the Earnings of the Earnings.

The best ways to invest in healthcare.

The Worldwide Healthcare Trust (LSE: WWH), which is run by expert investment advisor OrbiMed and has over £20 billion in assets under management with a focus on healthcare, is one way to play this theme. Over the past five years, the trust has been negatively impacted by its excessive exposure to China and biotech; however, this paid off in 2025, when it outperformed its peer group by seven percentage points. Since 2010, it has consistently outperformed the MSCI World Health Care by 2.3 percent annually. The shares' net asset value (NAV) is discounted by 7%.

Polar Capital Global Healthcare (LSE: PCGH) is more exposed to the undervalued healthcare sector than to biotech. Four years ago, the trust was trading at a 12 percent discount. This year, it has been issuing shares and is currently trading at a premium. Over the previous five years, it has surpassed its benchmark by 39.2%. Following a reorganization last year, it added 40 million (9.7 percent of NAV) in gearing, leaning toward low valuations.

International Biotechnology (LSE: IBT), RTW Biotech Opportunities (LSE: RTW), and the Biotech Growth Trust (LSE: BIOG) are all located on the more speculative end of the biotech spectrum. Despite their near double-digit discounts, investors should exercise greater caution due to their positioning.

Pharmakon, a specialist investor, oversees BioPharma Credit (LSE: BPCR), which adopts a different strategy by providing loans backed by businesses' pharmaceuticals and goods. It has an excellent track record, with the exception of one loan that hasn't done well since 2009. The trust yields 10.9% and trades at a 5% discount to NAV.